456 results match your criteria: "Centre d'Investigations Cliniques- Plurithématique 1433[Affiliation]"

Background: Cardiogenic shock (CS) is a heterogeneous clinical syndrome, making it challenging to predict patient trajectory and response to treatment. This study aims to identify biological/molecular CS subphenotypes, evaluate their association with outcome, and explore their impact on heterogeneity of treatment effect (ShockCO-OP, NCT06376318).

Methods: We used unsupervised clustering to integrate plasma biomarker data from two prospective cohorts of CS patients: CardShock (N = 205 [2010-2012, NCT01374867]) and the French and European Outcome reGistry in Intensive Care Units (FROG-ICU) (N = 228 [2011-2013, NCT01367093]) to determine the optimal number of classes.

View Article and Find Full Text PDF

Background: Growth differentiation factor (GDF)-15 is a pleiotropic cytokine that is associated with appetite-suppressing effects and weight loss in patients with malignancy.

Objectives: This study aims to investigate the relationships between GDF-15 levels, anorexia, cachexia, and clinical outcomes in patients with advanced heart failure with reduced ejection fraction (HFrEF).

Methods: In this observational, retrospective analysis, a total of 344 patients with advanced HFrEF (age 58 ± 10 years, 85% male, 67% NYHA functional class III), underwent clinical and echocardiographic examination, body composition evaluation by skinfolds and dual-energy x-ray absorptiometry, circulating metabolite assessment, Minnesota Living with Heart Failure Questionnaire, and right heart catheterization.

View Article and Find Full Text PDF

We Need Simpler and More Integrated Guidelines in Cardio-Kidney-Metabolic Diseases.

JACC Heart Fail

January 2025

Centre d'Investigations Cliniques Plurithématique 1433, INSERM, Université de Lorraine, CIC 1439, Institut Lorrain du Coeur et des Vaisseaux, CHU 54500, Vandoeuvre-lès-Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), INSERM U1116, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.

View Article and Find Full Text PDF
Article Synopsis
  • The study aims to assess the safety and efficacy of using expanded CD34+ cells for treating patients with acute myocardial infarction (AMI) and reduced left ventricular function, crucial for improving patient outcomes.
  • Patients with severe AMI (left ventricular ejection fraction <50%) are randomly assigned to receive either CD34+ cell treatment alongside standard care or standard care only, with a focus on monitoring major adverse cardiac events over six months.
  • This trial is groundbreaking as it explores the automated expansion and administration of autologous CD34+ cells, addressing current technological limitations in cell therapy for heart recovery post-AMI.
View Article and Find Full Text PDF

Anaemia, erythrocytosis, and empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.

Eur Heart J

December 2024

Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.

View Article and Find Full Text PDF

The Win Ratio for Composite Outcomes in Nephrology Clinical Trials.

J Am Soc Nephrol

December 2024

INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, CHRU de Nancy and F-CRIN INI-CRCT, Université de Lorraine, Nancy, France.

View Article and Find Full Text PDF
Article Synopsis
  • The study aims to use machine learning clustering to categorize distinct patient types among those with ischaemic heart failure and reduced ejection fraction (HFrEF) to improve personalized treatment approaches.
  • Analysis of 8,591 HFrEF patients revealed five unique clusters based on clinical and biological traits, with varying risks for hospitalization and death, highlighting the need for tailored management strategies.
  • The findings indicate that specific clusters correlate with different outcomes, suggesting that treatments like mineralocorticoid receptor antagonists may be more beneficial for certain patient groups, ultimately enhancing patient care in the future.
View Article and Find Full Text PDF

Mineralocorticoid Receptor and Sleep Quality in Chronic Kidney Disease.

Int J Mol Sci

November 2024

Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid-CSIC, 47003 Valladolid, Spain.

The classical function of the mineralocorticoid receptor (MR) is to maintain electrolytic homeostasis and control extracellular volume and blood pressure. The MR is expressed in the central nervous system (CNS) and is involved in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis as well as sleep physiology, playing a role in the non-rapid eye movement (NREM) phase of sleep. Some patients with psychiatric disorders have very poor sleep quality, and a relationship between MR dysregulation and this disorder has been found in them.

View Article and Find Full Text PDF
Article Synopsis
  • - The study evaluated cardiologists' awareness and implementation of advanced heart failure (HF) guidelines, revealing significant knowledge gaps, especially among general cardiologists and other participants compared to heart failure specialists.
  • - An online survey collected data from 497 cardiologists across Europe, highlighting that 84% of heart failure cardiologists regularly used ESC/HFA criteria for advanced HF, while only 44% of general cardiologists did.
  • - The findings emphasize the need for increased education on advanced HF guidelines and improvements in the referral process to ensure patients receive timely and appropriate care.
View Article and Find Full Text PDF

Centrally adjudicated vs. investigator-reported outcomes in randomized heart failure trials.

Eur Heart J

December 2024

Development, Novartis Pharma AG, Forum 1, Novartis Campus, CH-4056 Basel, Switzerland.

Article Synopsis
  • Heart failure events in cardiovascular trials are often evaluated through centralized review, but its impact on treatment effect accuracy (in terms of hazard ratios) is uncertain.
  • In a study of seven trials, positive adjudication rates for heart failure events were generally lower than for cardiovascular deaths, affecting subsequent mortality risk.
  • Overall, while central adjudication showed some correlation between event types, it didn’t significantly change the results, suggesting that the need for centralized review should be tailored to each trial's objectives.
View Article and Find Full Text PDF

Aims: To describe the clinical practice and educational preparation of heart failure (HF) nurses across Europe and determine the key differences between countries.

Methods And Results: A survey tool was developed, in English, by the Heart Failure Association Patient Care committee of the European Society of Cardiology (ESC). It was translated into eight languages, before electronically disseminated by nurse ambassadors, presidents of HF national societies and through social media.

View Article and Find Full Text PDF

Introduction: Sodium glucose co-transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRAs) reduce the progression of kidney disease. Whether the combination of these agents provides additional benefits compared to SGLT2i alone is worth exploring using data from randomized trials designed for this purpose. The aim of the study was to assess the randomized treatment effect of MRAs combined with SGLT2i versus SGLT2i alone on markers of kidney and cardiovascular health.

View Article and Find Full Text PDF

Aims: Biomarkers associated with asymptomatic ventricular dysfunction might improve risk stratification and identify pathways leading to heart failure (HF). We explored the association between proteomic biomarkers and left ventricular hypertrophy (LVH), diastolic dysfunction (DD) and incident HF in three population-based cohorts.

Methods And Results: A chip was used to measure 92 protein biomarkers in blood samples from >1500 Malmö Preventive Project (MPP) participants, of whom 514 had LVH (34%), 462 had DD (32.

View Article and Find Full Text PDF

Background: Cognitive impairment is common in patients with heart failure and preserved ejection fraction but its clinical correlates and prognostic associations are poorly understood.

Methods: We analyzed cognitive function, using the Mini-Mental State Examination (MMSE), in patients with heart failure and preserved ejection fraction enrolled in a prespecified substudy of the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction). Logistic regression analyses were performed to determine the variables associated with lower MMSE scores at baseline and postbaseline decline in MMSE scores at 48 weeks.

View Article and Find Full Text PDF

Lung ultrasound (LUS) is a simple, fast and non-invasive tool for pulmonary congestion assessment with higher accuracy for the detection of acute heart failure (HF) compared to clinical examination and chest radiography. The integrated assessment with other ultrasound and echocardiographic parameters can lead to a better systemic and pulmonary congestion characterization. Additionally, the combination of echocardiographic and pulmonary features can identify patients at higher risk for adverse outcomes, potentially facilitating both acute and chronic HF management and prognostic stratification.

View Article and Find Full Text PDF
Article Synopsis
  • - The article discusses the growing popularity of the win ratio method in cardiovascular trials, highlighting its advantages over conventional composite outcomes and its various applications for analyzing clinical data.
  • - Key topics covered include the workings and interpretation of the win ratio, guidelines for selecting clinical outcomes, and additional measures like the win difference to assess absolute benefits in studies.
  • - It emphasizes the need for correct application, discusses potential misuses, and provides recommendations for future research, complemented by examples from cardiology trials and included statistical methods.
View Article and Find Full Text PDF
Article Synopsis
  • - Patients with chronic kidney disease (CKD) are at increased risk for heart-related issues, and medications like SGLT2 inhibitors (Dapagliflozin) and MRAs (Eplerenone) can help with cardiovascular problems, especially in diabetic cases.
  • - A study tested the effects of Dapagliflozin and Eplerenone together on heart and kidney functions in rats with non-diabetic CKD, revealing that both drugs reduced kidney fibrosis and improved heart pressure and perfusion.
  • - The combined treatment of Dapagliflozin and Eplerenone not only improved heart function but also showed a synergetic effect in reducing heart muscle damage compared to using each drug alone.
View Article and Find Full Text PDF

Subclinical left ventricular dysfunction in rheumatoid arthritis: findings from the prospective Porto-RA cohort.

Clin Res Cardiol

September 2024

Department of Cardiology, Unidade Local de Saúde de Santo António, Largo Do Prof. Abel Salazar, 4099-001, Porto, Portugal.

Aim: Patients with rheumatoid arthritis (RA) have an increased risk of cardiac dysfunction and heart failure (HF) due to a pro-inflammatory state. Detecting cardiac dysfunction in RA is challenging as these patients often present preserved ejection fraction (EF) but may have subclinical ventricular dysfunction. Echocardiographic strain analysis is a promising tool for early detection of subclinical left ventricular systolic dysfunction (LVSD).

View Article and Find Full Text PDF

Patiromer and MRA Doses in Patients With Current or Past Hyperkalemia.

JACC Heart Fail

December 2024

UnIC@RISE, Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal; Heart Failure Clinic, Internal Medicine Department, Unidade Local de Saúde de Gaia/Espinho, Portugal and Centre d'Investigations Cliniques Plurithématique 1433, INSERM, Université de Lorraine, Nancy, France; F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), INSERM U1116, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France. Electronic address:

View Article and Find Full Text PDF

Aim: To identify unique clinical phenotypes in type 2 diabetes (T2D) and investigate their treatment response to canagliflozin using latent class analysis.

Methods: This was a pooled latent class analysis of the individuals in the CANVAS Program and CREDENCE trial. The co-primary endpoints were hospitalization for heart failure (HHF) and the composite of cardiovascular death (CVD) or HHF.

View Article and Find Full Text PDF